The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma

作者：Pei‐Yu Yang, Fan Zhou, Yujun Dong, Guangxun Gao, Hua Xue, Xinyue Liang, Shanshan Yu, Weiling Xu, Yanping Ma, Xiaoqi Qin, Mengyao Li, Yun Dai, Fengyan Jin · 发表于：HemaSphere · 年份：2023 · DOI：10.1097/hs9.0000000000000857 · 被引用次数：10 · 研究领域：Multiple Myeloma Research and Treatments、Peptidase Inhibition and Analysis、Protein Degradation and Inhibitors

Multiple myeloma (MM) is a complex disease with highly heterogeneous tumor biology, especially involving cytogenetic abnormalities.1 Consequently, MM patients display markedly diverse clinical characteristics, therapeutic responses, and outcomes.2,3 In this context, the international staging system (ISS) was developed to predict the prognosis of MM patients in 2005,4 which was later updated and named revised ISS (R-ISS) in 2015.5 Although the R-ISS has widely been used as a powerful tool to guide daily practice till present, some considerable limitations (eg, a large proportion of R-ISS II patients with varied outcomes, not reflecting the significance of 1q gain/amplification and concurrent high-risk cytogenetic abnormalities [HRCAs]) have been emerging.6–9 In this context, several new prognostic scoring systems have been reported,10,11 the most recent of which is the second revision of ISS (R2-ISS) updated by the European Myeloma Network (EMN).12 In the R2-ISS,12 5 risk variates with the highest impact on both progression-free survival (PFS) and overall survival (OS) were weighted according to their OS impact, including ISS III 1.5, ISS II 1.0, del(17p) 1.0, lactate dehydrogenase high 1.0, t(4;14) 1.0, and 1q+ (either 1q gain or amplification) 0.5. However, t(14;16) was not included because patients with this HRCA had only a trend toward a shorter PFS than those without it, but not statistically significant, although its role was significant in predicting OS. According to th...